Harnessing the MYB-dependent TAL1 5’super-enhancer for targeted therapy in T-ALL

Harnessing the MYB-dependent TAL1 5’super-enhancer for targeted therapy in T-ALL

Abstract The acquisition of genetic abnormalities engendering oncogene dysregulation underpins cancer development. Certain proto-oncogenes possess several dysregulation mechanisms, yet how each mechanism impacts clinical outcome is unclear. Using T-cell acute lymphoblastic leukemia (T-ALL) as an exa...

Full description

Bibliographic Details
Main Authors: Charlotte Smith, Aurore Touzart, Mathieu Simonin, Christine Tran-Quang, Guillaume Hypolite, Mehdi Latiri, Guillaume P. Andrieu, Estelle Balducci, Marie-Émilie Dourthe, Ashish Goyal, Françoise Huguet, Arnaud Petit, Norbert Ifrah, André Baruchel, Hervé Dombret, Elizabeth Macintyre, Christoph Plass, Jacques Ghysdael, Nicolas Boissel, Vahid Asnafi
Format: Article
Language:English
Published: BMC 2023-01-01
Series:Molecular Cancer
Subjects:
Super-enhancer
Oncogene
Targeted therapy
Cancer
Online Access:https://doi.org/10.1186/s12943-022-01701-x

Internet

https://doi.org/10.1186/s12943-022-01701-x

Similar Items